Table 3 Pooled relative risk of all grade and high grade irAEs for combination vs nivolumab
All grade irAEs | No. of trials | Pooled RR (95% CI) | Pooled RR | p Value | High grade irAEs | No. of trials | Pooled RR (95% CI) | Pooled RR | p Value |
|---|---|---|---|---|---|---|---|---|---|
Total incidence | 2 | 1.067–1.254 | 1.157 | 0.000 | Total incidence | 2 | 1.337–2.089 | 1.672 | 0.000 |
Discontinuation | 2 | 1.062–1.975 | 1.448 | 0.019 | Discontinuation | 1 | 1.133–2.656 | 1.735 | 0.011 |
Fatigue | 2 | 0.550–1.660 | 0.956 | 0.872 | Fatigue | 2 | 0.720–11.245 | 2.845 | 0.136 |
Pruritis | 2 | 1.320–2.736 | 1.900 | 0.001 | Pruritis | 2 | 0.245–91.337 | 4.731 | 0.304 |
Rash | 2 | 0.508–2.391 | 1.102 | 0.806 | Rash | 2 | 0.491–4.239 | 1.442 | 0.506 |
Hyperthyroidism | 2 | 0.947–13.480 | 3.573 | 0.060 | Hyperthyroidism | 1 | 0.188–111.215 | 4.577 | 0.350 |
Hypothyroidism | 2 | 1.170–2.828 | 1.819 | 0.008 | Hypothyroidism | 1 | 0.124–14.921 | 1.358 | 0.803 |
Nausea | 2 | 1.066–2.482 | 1.626 | 0.024 | Nausea | 2 | 0.323–12.855 | 2.037 | 0.449 |
Vomiting | 2 | 0.877–3.123 | 1.655 | 0.120 | Vomiting | 2 | 0.232–10.670 | 1.573 | 0.643 |
Decreased appetite | 1 | 1.282–3.064 | 1.982 | 0.002 | Decreased appetite | 1 | 0.246–91.812 | 4.156 | 0.302 |
Constipation | 1 | 1.069–6.332 | 2.602 | 0.035 | Constipation | 1 | – | – | – |
Diarrhea | 2 | 1.092–2.037 | 1.491 | 0.012 | Diarrhea | 2 | 0.514–5.392 | 1.664 | 0.396 |
Pneumomitis | 1 | 0.353–5.161 | 1.351 | 0.660 | Pneumomitis | 1 | 0.217–18.948 | 2.026 | 0.536 |